Pacific Biosciences Q3 revenue slightly beats expectations on SPRQ-Nx adoption
PACB•Pacific Biosciences reported Q3 revenue of $40.6 million, slightly above the $40.39 million consensus, and adjusted loss per share of $0.11 versus expected $0.15. The company expects 2026 revenue of $155 million to $160 million.
1. Quarterly results
Q3 revenue was $40.6 million, slightly above analyst expectations of $40.39 million. Adjusted loss per share was $0.11, compared with the expected $0.15, while adjusted gross margin was 36%.
2. Revenue and outlook
The company said increased SPRQ-Nx adoption drove Revio consumables revenue and software upgrades. It delivered 35 new Vega systems, mostly to new customers, and expects 2026 revenue of $155 million to $160 million. Pacific Biosciences said higher memory costs and the Vega transition may affect margins.
